Association of Systemic Inflammatory Biomarkers (NLR, MLR, PLR, SII, SIRI) with Preeclampsia-Related Kidney Injury: A Retrospective Observational Study

系统性炎症生物标志物(中性粒细胞与淋巴细胞比值、单核细胞与淋巴细胞比值、血小板与淋巴细胞比值、系统性炎症反应指数、系统性炎症反应指数)与先兆子痫相关肾损伤的关联:一项回顾性观察研究

阅读:1

Abstract

BACKGROUND: Approximately 7-13% of pregnant women with preeclampsia (PE) develop acute kidney injury (AKI), which is one of the most serious complications of PE and is linked to long-term chronic kidney disease. This retrospective observational study investigated the association between inflammation indices and PE-related acute kidney injury (PE-AKI). METHODS: This retrospective study analyzed 4071 PE patients admitted between 2013 and 2023. Inflammatory indices, including neutrophil-to-lymphocyte ratio (NLR), monocyte-to-lymphocyte ratio (MLR), platelet-to-lymphocyte ratio (PLR), systemic immune-inflammation index (SII), and systemic inflammation response index (SIRI), were derived from complete blood counts. Multivariate logistic regression assessed associations with PE-AKI risk, with nonlinear relationships characterized using restricted cubic spline models. RESULTS: Among 4071 patients with PE, 290 (7.13%) developed AKI. Multivariate analysis (Model 3) revealed significant positive associations between log(2)-transformed inflammatory indices and PE-AKI risk, with the highest odds ratios observed for MLR (OR = 6.02, 95% CI: 4.68-7.73; P < 0.0001) and NLR (OR = 3.93, 95% CI: 3.09-5.01; P < 0.0001). MLR demonstrated the strongest independent correlation with PE-AKI (highest tertile OR = 7.24, 95% CI: 4.75-11.02), followed by SIRI (OR = 5.78, 95% CI: 3.89-8.59). All indices (NLR, MLR, PLR, SII, SIRI) exhibited linear dose-response relationships with PE-AKI risk (P-overall <0.001 for each). Subgroup analyses further identified elevated MLR as a prominent risk factor in early-onset PE (gestational age ≤32 weeks; OR = 8.81, 95% CI: 4.91-17.10) and patients with complications (OR = 7.28, 95% CI: 5.23-10.32). CONCLUSION: MLR and SIRI are positively associated with PE-AKI risk, particularly in early-onset and complicated cases. This first comprehensive assessment of five biomarkers supports clinical utility. Prospective validation is required, with focus on monocyte-mediated inflammatory mechanisms.

特别声明

1、本页面内容包含部分的内容是基于公开信息的合理引用;引用内容仅为补充信息,不代表本站立场。

2、若认为本页面引用内容涉及侵权,请及时与本站联系,我们将第一时间处理。

3、其他媒体/个人如需使用本页面原创内容,需注明“来源:[生知库]”并获得授权;使用引用内容的,需自行联系原作者获得许可。

4、投稿及合作请联系:info@biocloudy.com。